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Introduction
Triple-negative breast cancers (TNBCs) are defined as tumors 
negative for estrogen- (ER) and progesterone receptors (PR) with-
out HER2 amplification/overexpression.1 The clinical importance 
of this subgroup relates to poor prognosis and lack of treatment 
options. Currently, there are no established therapeutic targets for 
TNBCs leaving chemotherapy as the only effective treatment for 
these patients.2 The biological importance of TNBCs as a dis-
tinct disease entity was established through microarray-based 
gene expression studies showing five distinct subtypes.3 Of these, 
the basal-like subtype shows low or complete absence of ER and 
PR and lack overexpression of the HER2 gene. In concordance 
with this, most basal-like breast cancers classify as TNBCs.4 
More recently, a subtype of TNBCs characterized by features 
of mesenchymal and mammary stem cells was described and 
referred to as claudin-low in keeping with low expression of tight 
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is greatly increased in BRCA1 mutation carriers. This study aimed to assess the impact of BRCA1 promoter methylation 
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junction proteins including claudin-3, 4 and 7, and E-cadherin.5 
Importantly, residual tumor cells surviving chemotherapy are 
characterized by features associated with mesenchymal and tumor 
initiating cells, and are similar to claudin-low tumors.6
Inherited germline mutations in the BRCA1 tumor suppres-
sor gene confer greatly increased risk for developing breast can-
cer.7 The incidence of TNBC in BRCA1 mutation carriers is 
exceptionally high, or around 70%, and basal-like features are 
prominent among these tumors.8,9 Additionally, high histological 
grade and expression of proliferation markers are common both 
in sporadic TNBCs and BRCA1 mutated tumors.10 The genomes 
of breast tumors derived from BRCA1 carriers are highly rear-
ranged, and this is also observed in sporadic TNBCs.11 The 
shared characteristics with tumors arising in BRCA1 mutation 
carriers brought about the hypothesis that acquired defects in 
the BRCA1 gene could lead to the development of TNBCs in 
sporadic disease.12 Although somatic mutations in BRCA1 have www.landesbioscience.com Epigenetics  639
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Results
Tissue microarrays (TMAs) were constructed representing 
303 breast tumors derived from a well defined sample collec-
tion previously screened for the local 5193G→A  BRCA1 and 
999del5 BRCA2 germline mutations.23,24 Out of the 303 tumors 
samples, 292 were derived from sporadic cases wherein a set of 
111 tumors had previously been analyzed for CpG island hyper-
methylation of the BRCA1 gene.17,18 Additionally, we included a 
total of eight familial 5193G→A BRCA1 mutated tumors, along 
with three tumors derived from carriers of a polymorphism 5142 
ACT→TCT (Thr1675Ser) in exon 17 of the BRCA1 gene.
BRCA1 aberrations in sporadic- and familial breast can-
cers are associated with the basal/triple-negative phenotype. 
The effects of genetic and epigenetic defects in the BRCA1 gene 
were examined with respect to phenotype by looking at subtype-
specific markers, i.e., ER, PR, HER2, CK5/6, EGFR and Ki-67 
by IHC analysis on TMAs. Out of the 303 samples analyzed 
on TMAs, 286 were interpretable for subtype-specific markers 
analyzed on TMAs. In sporadic cases, the luminal-A (LumA) 
subtype was the most prevalent (119 of 275; 43%), followed by 
luminal-B (LumB) (84 of 275; 31%), triple-negative (TN) (53 of 
275; 19%) and HER2 (19 of 275; 7%). To determine the effects 
of  BRCA1 aberrations on phenotype, we compared sporadic 
tumors displaying CpG island hypermethylation of the BRCA1 
gene (n = 18) and familial tumors obtained from 5193G→A 
BRCA1 mutation carriers (n = 8) to those of non-BRCA1 
not been found, other mechanisms could lead to inactivation 
of the BRCA1 gene in sporadic disease.13 In this relation, gene 
silencing through epigenetic modifications has been established 
as an important mechanism for inactivation of tumor suppressor 
genes.14 Loss of BRCA1 expression through CpG island hyper-
methylation of the promoter region has been described in breast 
cancer.15,16 Importantly, epigenetic inactivation of the BRCA1 
gene is associated with pathological features that are also preva-
lent in tumors derived from BRCA1 mutation carriers including 
ER negativity and the special histological types medullary and 
mucinous types.15 We have previously demonstrated that CpG 
island hypermethylation of the BRCA1 gene occurs in approxi-
mately 10% of all sporadic breast cancers, and that epigenetic 
silencing of BRCA1 leads to similar patterns of genetic changes 
as those observed in BRCA1 mutated tumors.17,18 Collectively, 
these observations have established epigenetic inactivation of the 
BRCA1 gene as an important event in sporadic breast cancer. It is, 
however, not yet clear whether epigenetic inactivation and tran-
scriptional silencing of the BRCA1 gene specifically relate to the 
development of TNBCs or basal-like breast cancers in sporadic 
cases, similar to that which occurs in BRCA1 mutation carriers. 
There are contradictory data where some reports have described 
loss of BRCA1 expression in association with the basal-like sub-
type,19,20 but others have not found the same.21,22 In this study, we 
used tissue microarrays to examine sufficiently large number of 
sporadic breast cancers to explore the relationship between sub-
type-specific markers and BRCA1 promoter hypermethylation.
Table 1. BRCA1 gene aberrations with respect to breast cancer subtypes in sporadic and familial breast cancer
Breast Cancer Subtypes LumA LumB HER2 Basal/TN
BRCA1 methylated (n = 18) [Sporadic] 5 (28%) 2 (11%) 1 (5%) 10 (56%)
Not BRCA1 methylated (n = 59) [Sporadic]a, b 25 (42%) 21 (36%) 3 (5%) 10 (17%)
Chi-Squared test; X2 = 12.9, P = 0.012
BRCA1 mutated (n = 8) [Familial] 0 2 (26%) 1 (12%) 5 (62%)
Not BRCA1 mutated (n = 26) [Sporadic]a 14 (54%) 7 (27%) 2 (8%) 3 (11%)
Chi-Squared test; X2 = 11.2, P = 0.011









BRCA1 methylated (n = 18) [Sporadic] 9 (50%) 8 (44%) 1 (6%)
No BRCA1 methylated (n = 61) [Sporadic]a 6 (10%) 21 (34%) 34 (56%)
Chi-Squared test; X2 = 20.1, P = 
0.0002
BRCA1 mutated (n = 8) [Familial] 6 (75%) 2 (25%) 0
No BRCA1 mutated (n = 25) [Sporadic]a,c 5 (20%) 3 (12%) 17 (68%)
Chi-Squared test; X2 = 11.6, P = 0.003
a, matched against the BRCA1 affected group with respect to age- and year at diagnosis; b, two cases had missing 
information with respect to subtype-specific markers; c, one case had missing information with respect to BRCA1 
expression.640  Epigenetics  Volume 6 Issue 5
5142 ACT→TCT polymorphic BRCA1 tumors (Table 1). The 
effects of CpG island hypermethylation of the BRCA1 promoter 
on expression were validated by IHC analysis for BRCA1 gene 
products on tissue microarrays (TMAs) demonstrating a sig-
nificant association (Table 1). Of interest in this relation is that 
BRCA1 mutated tumors were also found to be associated with 
loss of BRCA1 gene products (Table 1).
affected tumors matched for age-and year at diagnosis (n = 85)   
(Table 1; Sup. Table 2 and Sup. Fig. 1). This analysis demon-
strates that CpG island hypermethylation of the BRCA1 gene 
significantly associates with the triple-negative (TN) phenotype 
in sporadic disease (Table 1). Similarly, the 5193G→A BRCA1 
mutated tumors were also enriched for the TN phenotype, 
whereas this phenotype was not identified in any of the three 
Table 2. Characterization of breast cancer subtypes with respect to selected markers analyzed by immunohistochemistry (IHC)
Subtype LumA* LumB** HER2 TN***
BRCA1 Null/Weak (<10%) 11 (10%) 8 (9%) 6 (29%) 20 (35%)
Intermediate/High (>10%) 100 (90%) 77 (91%) 15 (71%) 37 (65%)
Chi-Squared X2 = 23.2; P = 4 × 10-5
p16 (CDKN2A) Null/Weak <10% 50 (47%) 37 (43%) 8 (38%) 14 (25%)
Intermediate 10 - 50% 52 (49%) 44 (51%) 7 (33%) 5 (9%)
High/Intense >50% 5 (5%) 5 (6%) 6 (29%) 38 (67%)
Chi-Squared X2 = 108.0; P < 1 × 10-10
pRb (RB1) Null/Weak <10% 4 (3%) 3 (3%) 1 (5%) 24 (42%)
Intermediate 10 - 50% 28 (25%) 17 (20%) 6 (29%) 10 (17%)
High >50% 82 (72%) 66 (77%) 14 (67%) 23 (40%)
Chi-Squared X2 = 67.5; P < 1 × 10-10
p53 (TP53) Null/Weak <10% 36 (32%) 21 (25%) 5 (24%) 20 (34%)
Intermediate 10 - 50% 73 (64%) 52 (61%) 4 (19%) 16 (28%)
High/Intense >50% 5 (4%) 12 (14%) 12 (57%) 22 (38%)
Chi-Squared X2 = 59.4; P < 1 × 10-10
PTEN Null (<1%) 10 (9%) 12 (14%) 3 (14%) 21 (37%)
Positive (>1%) 105 (91%) 73 (86%) 18 (86%) 36 (63%)
Chi-Squared X2 = 22.6; P = 5 × 10-5
CK8 (KRT8) Null/Weak <10% 1 (1%) 1 (1%) 2 (9%) 31 (54%)
Intermediate (10 - 80%) 11 (9%) 5 (6%) 3 (14%) 20 (35%)
High/Intense (>80%) 104 (90%) 80 (93%) 16 (76%) 6 (11%)
Chi-Squared X2 = 164.9; P < 1 × 10-10
CK18 (KRT18) Null/Weak <10% 2 (2%) 1 (1%) 0 14 (25%)
Intermediate (10 - 80%) 5 (4%) 3 (3%) 1 (5%) 24 (42%)
High/Intense (>80%) 108 (94%) 82 (95%) 20 (95%) 19 (33%)
Chi-Squared X2 = 116.5; P < 1 × 10-10
MUC1 Null/Weak <10% 14 (12%) 6 (7%) 3 (14%) 17 (30%)
Intermediate (10 - 80%) 55 (49%) 30 (35%) 3 (14%) 19 (34%)
High >80% 44 (39%) 50 (58%) 15 (71%) 20 (36%)
Chi-Squared X2 = 28.3; P = 8 × 10-5
EGFR Null <1% 112 (98%) 82 (96%) 11 (52%) 14 (25%)
Weak (1 - 50%) 1 (1%) 2 (2%) 2 (10%) 10 (17%)
High/Intense (>50%) 1 (1%) 1 (1%) 8 (38%) 33 (58%)
Chi-Squared X2 = 153.6; P < 1 × 10-10
CK5/6 (KRT5/6) Null (<1%) 104 (90%) 78 (93%) 16 (76%) 20 (34%)
Positive (>1%) 12 (10%) 6 (7%) 5 (24%) 38 (66%)
Chi-Squared X2 = 84.4; P < 1 × 10-10
Claudin-3 
(CLDN3)
Null (<1%) 8 (7%) 3 (3%) 0 5 (9%)
Positive (>1%) 108 (93%) 83 (97%) 21 (100%) 53 (91%)
Chi-Squared X2 = 3.3; P = 0.35www.landesbioscience.com Epigenetics  641
pattern was found to be related to more favorable disease outcome, 
where high/intense p16 was statistically significant (Fig. 2B). 
Additionally, the relatively few breast cancer patients with tumors 
of the TN/Claudin-Low phenotype, defined as TN breast tumors 
with complete loss of Claudin-3 expression, were associated with 
reduced survival (Fig. 2B). To account for the TN/Claudin-Low 
subtype, we classified triple-negative breast cancers into three 
prognostic subgroups based on the following scheme; Firstly, TN 
tumors that lack expression of Claudin-3 (null) are classified as 
TN/Claudin-Low; Secondly, the remaining tumors (TN) are 
classified based on the presence or absence of high/intense p16 
levels referred to as TN/Claudin+/RB- (loss) or TN/Claudin+/
RB+, respectively. This classification scheme identifies TN sub-
groups with substantial differences in disease outcomes (Fig. 2C). 
Of particular importance in this respect is that the proportions of 
tumor cells positive for Ki-67, a marker of cellular proliferation, 
were significantly lower in the poor prognostic subgroups, i.e., 
TN/Claudin- and TN/Claudin+/RB+ (Fig. 3A). The optimal cut-
points for Ki-67 in predicting disease outcomes were different in 
TN- and luminal subtypes, whereas no survival-dependent effects 
for Ki-67 were identified within the HER2 subtype (Fig. 3B). 
Evidently, TN breast tumors displaying high levels of prolifera-
tion, i.e., ≥40%, associate with favorable disease outcomes with 
breast cancer-specific deaths observed in only 6% of these patients 
(2 of 34). This survival rate is similar to, and even better than that 
observed in luminal breast tumors displaying low levels of Ki-67 
positive tumor cells, namely the LumA subtype (Fig. 3C).
Discussion
The results presented here demonstrate that BRCA1 defects 
and RB/p16 dysfunction are co-occurring events in the devel-
opment of triple-negative breast cancer (TNBC). Importantly, 
RB/p16 dysfunction was seen in association with acquired CpG 
island hypermethylation of the BRCA1 gene, as well as in tumors 
derived from BRCA1 mutation carriers. Additionally, TNBCs 
with RB/p16 dysfunction were characterized by high p53, loss 
of PTEN and high Ki-67 (highly proliferative). Given the link 
to BRCA1 defects, we hypothesize that this phenotype i.e., RB/
p16 dysfunctional TNBCs could be promoted by DNA repair 
defects, a feature associated with enhanced sensitivity to DNA 
damaging agents often used in treatment of hormone-receptor 
negative disease. This could explain the association with favor-
able disease outcomes for patients with TNBC of the RB/p16 
dysfunctional type. The clinical significance of our findings 
relates to the potential use of less toxic and more targeted treat-
ment based on PARP inhibitors in sporadic cases of TNBC, 
wherein CpG island hypermethylation of the BRCA1 gene could 
be an important predictor of therapeutic response.
We have previously reported that CpG island hypermethyl-
ation of the BRCA1 gene occurs in ~10% of sporadic breast can-
cers, and that epigenetic silencing of BRCA1 in sporadic tumors 
leads to genomic changes similar to those observed in tumors 
derived from BRCA1 mutation carriers.17,18 Here, we have char-
acterized the phenotype of sporadic tumors with acquired CpG 
island hypermethylation of the BRCA1 gene on tissue microarrays 
The assigned subtypes strongly associate with histological 
grade, with grade I mostly confined to LumA, and grade II being 
either of LumA or LumB, and grade III mostly of TN/Basal, 
LumB or HER2 subtypes (Sup. Table 3). Ductal carcinomas 
dominate all subtypes with other histological types being con-
siderably less frequent wherein lobular carcinomas were mostly 
confined to the LumA subtype, and medullary features mostly 
of TN/basal or HER2 subtypes (Sup. Table 3). The large major-
ity of sporadic tumors with CpG island hypermethylation of the 
BRCA1 gene were of the ductal type, similar to that observed in 
tumors derived from BRCA1 mutation carriers, and no signifi-
cant associations were identified with respect to tumor morphol-
ogy in this respect (Sup. Table 4).
Characterization of TN breast cancers with respect to 
BRCA1 aberrations. To characterize the group of triple-negative 
tumors, a set of eight markers were selected based on published lit-
erature in relation to the basal-like phenotype, including markers 
of the DNA damage response, cell cycle progression and cellular 
phenotype, i.e., BRCA1, p53 (TP53), PTEN, p16 (CDKN2A), 
pRb (RB1), MUC1, CK8 (KRT8), CK18 (KRT18), CK5/6 
(KRT5/6), EGFR and Claudin-3. This analysis shows that triple-
negative breast cancers are characterized by null/weak BRCA1 
expression, high/intense p16 (CDKN2A), null/weak pRb (RB1), 
negativity for PTEN, high/intense p53, weak/null MUC1, inter-
mediate or low CK8/CK18, and positivity for CK5/6 and EGFR 
(Table 2). Cluster analysis based on these characteristics suggests 
that triple-negative breast cancers can be sub-categorized into 
two groups that differ with respect to pRb, p16, BRCA1 and 
PTEN, while similar with respect to CK8, CK18, CK5/6 and 
EGFR (Fig. 1A–C). Based on this model, loss of pRb expres-
sion coupled with high p16 levels, hereafter referred to as pRblow/
p16high, and negativity for PTEN along with weak/null BRCA1 
expression are highly coordinated expression patterns (Fig. 1B). 
Here, we find that sporadic tumors displaying CpG hypermeth-
ylation of the BRCA1 gene mostly pertain to the same cluster of 
triple-negative tumors as the familial 5193G→A BRCA1 mutated 
tumors (Fig. 1C). In line with this, the pRblow/p16high pattern 
(indicating RB/p16 dysfunction) was found to be associated 
with sporadic tumors displaying CpG island hypermethylation 
of the BRCA1 gene and, importantly, familial cases derived 
from 5193G→A BRCA1 germline mutation carriers (Table 3). 
Notably, familial BRCA1 mutated tumors, and sporadic tumors 
with acquired CpG island hypermethylation of the BRCA1 gene, 
when coupled with RB/p16 dysfunction (pRblow/p16high), almost 
exclusively results in the TN subtype (Sup. Table 5).
Disparities in survival of patients with basal/triple-negative 
breast tumors. Consistent with previous studies, we find strong 
prognostic value associated with the assigned breast cancer sub-
types wherein the basal-like, LumB and HER2 subtypes asso-
ciate with poor prognosis (Fig. 2). The high fraction of basal/
TN features in BRCA1 affected tumors, whether sporadic or 
familial, is suggestive of prognostic effects. However, neither spo-
radic breast tumors displaying CpG island hypermethylation of 
the BRCA1 gene, nor familial 5193G→A mutated tumors, were 
associated with patient survival (Sup. Fig. 2A). Nevertheless, 
looking exclusively at TN tumors, the pRblow/p16high expression 642  Epigenetics  Volume 6 Issue 5
Currently, there is no internationally accepted definition of 
the basal-like phenotype, although it is widely accepted that 
most TNBCs are basal-like, and positivity for either CK5/6 
or EGFR is often used to identify basal-like breast cancers.4,30 
In this respect, we found a strong association between TNBCs 
and positivity for the basal-like markers CK5/6 and EGFR, 
with either marker expressed in the large majority of all BRCA1 
mutated TNBCs (80%; 4 of 5) and similarly in sporadic TNBCs 
with acquired CpG hypermethylation of the BRCA1 gene (80%; 
8 of 10) (Sup. Table 2). Very few studies have analyzed basal 
markers in sporadic tumors with known CpG island hyper-
methylation of the BRCA1 gene, although ER negativity has 
been consistently reported as an associated feature.16,17,31 One 
study has reported similar frequencies of BRCA1 methylation in 
sporadic tumors with basal-like phenotype and a control group 
(TMA) by comparing them to sporadic tumors, unmethylated at 
the BRCA1 gene promoter, matched for age- and year at diagno-
sis. This comparison shows that CpG island hypermethylation 
of the BRCA1 gene is associated with TNBC and, importantly, 
that this same effect is observed in tumors derived from BRCA1 
mutation carriers. It has been proposed that the basal/TNBC 
phenotype can be useful in selecting patients for BRCA1 muta-
tion testing, and to classify variants of unknown significance in 
terms of disease predisposition.8,29 We therefore included tumors 
derived from carriers of a BRCA1 polymorphism, currently of 
unknown significance, that is 5142 ACT→TCT (Thr1675Ser). 
The results show that none of the BRCA1 polymorphic tumors 
classify as TNBC, implying that this polymorphism is not patho-
genic, or at least that it does not influence the course of tumor 
progression similar to that seen in BRCA1 mutation carriers.
Figure 1. BRCA1, pRb, p16 and PTEN define a sub-class within triple-negative (TN) breast cancers. (A) Hierarchical cluster analysis for the IHC expres-
sion profiles suggesting sub-structure within the TN subtype with at least two branches enriched for the basal/triple-negative phenotype. (B) The as-
sociation matrix for IHC markers representing the log-transform of adjusted p-values (Bonferroni adjustment for multiple testing) derived from Fishers 
exact hypothesis testing of pair-wise comparisons revealing two groups of strong correlative relationships, i.e., the expression profiles of BRCA1, PTEN, 
pRb and p16 more strongly correlate with each other than to CK8, CK18, CK5/6 and EGFR. The Bonferroni adjusted p-values are shown and represented 
in a spectrum of blue colors ranging from <10-10 (deep blue) to <0.05 (light blue) and N.S = Not Significant (white). (C) Hierarchical cluster analysis per-
formed separately on each of four main subtypes demonstrating that the TN subtype can be subdivided into two groups based on the co-ordinated 
expression of BRCA1, pRb, p16 and PTEN. Here, the familial tumors derived from BRCA1 mutation carriers along with sporadic tumors displaying CpG 
island hypermethylation predominantly cluster within the left branch (orange bar). The presence/absence of BRCA1 gene aberrations are indicated in 
cyan/black at the bottom of each dendrogram with white blanks representing unknown status.www.landesbioscience.com Epigenetics  643
We demonstrate that the expression patterns of BRCA1, pRb, 
p16, PTEN and p53 are highly correlated with one another, and 
that these markers define a subgroup of TNBCs associated with 
genetic or epigenetic defects in the BRCA1 gene. High/intense 
expression of p16 and loss of pRb are known to be associated 
events in breast cancer, and have been described as defining 
characteristics of basal-like breast cancer.32 The retinoblastoma 
1 gene (RB1) is a well known tumor suppressor gene with func-
tions in regulating cell cycle progression, and in mediating 
response to DNA damage, and is a critical component of the 
cellular senescence program.33 The pRblow/p16high expression pat-
tern is thought to reflect genetic mutations or epigenetic silenc-
ing of the retinoblastoma 1 gene (RB1) leading to loss of RB1 
gene products thereby alleviating transcriptional silencing of 
p16 (CDKN2A). Consistent with this, high expression of p16 is 
associated with loss of heterozygosity at the RB1 gene locus and 
both are prominent characteristics of the basal-like phenotype.34   
matched for histological grade and age at diagnosis.19 Our data, 
based on a larger number of samples, shows that the incidence of 
basal/TNBC in BRCA1 methylated tumors is higher than can 
be expected by chance (50%; 9 of 18) and that this frequency 
is similar in BRCA1 mutated tumors (62%; 5 of 8). Using the 
definition of basal-like as proposed by Nielsen et al. i.e., TNBCs 
positive for either CK5/6 or EGFR, leads to the same result (Sup. 
Table 2). Additionally, we find that CpG island hypermethyl-
ation of the BRCA1 gene in sporadic cases of TNBC cannot be 
explained by special histological types, as the large majority of 
these tumors classify as ductal carcinomas not otherwise speci-
fied (89%; 8 of 9 TNBC w/BRCA1 methylation) and, similarly, 
most of the BRCA1 mutated TNBCs are also of the ductal type 
(80%; 4 of 5 TNBCs in BRCA1 carriers) (Sup. Table 4). Taken 
together, our results are consistent with an important role for 
CpG island hypermethylation of the BRCA1 gene in promoting 
the development of basal/TNBC in sporadic cases of the disease.
Table 3. Genetic and epigenetic defects in the BRCA1 gene with respect to expression of p16, pRb and PTEN by immunohistochemistry (IHC)
p16 (CDKN2A)   Null/Weak/Intermediate (≤50%) High/Intense (≥50%)
  BRCA1 methylated (n = 18) [Sporadic] 9 (50%) 9 (50%)
  Not BRCA1 methylated (n = 60) [Sporadic]b,c 48 (80%) 12 (20%)
  Chi-Squared χ2 = 4.9; p = 0.03
  BRCA1 mutated (n = 8) [Familial] 3 (38%) 5 (62%)
  Not BRCA1 mutated (n = 25) [Sporadic]b,c 22 (88%) 3 (12%)
  Chi-Squared χ2 = 5.9; p = 0.01
  BRCA1 Null/Weak (n = 38) (IHC < 10%) [Sporadic] 20 (53%) 18 (47%)
  BRCA1 positive (n = 230) (IHC ≥ 10%) [Sporadic]a 197 (86%) 33 (14%)
  Chi-Squared χ2 = 21.0; p = 5 x 10-6
pRb (RB1)   Null/Weak (<10%) Intermediate/High (≥10%)
  BRCA1 methylated (n = 18) [Sporadic] 6 (33%) 12 (67%)
  Not BRCA1 methylated (n = 60) [Sporadic]b,c 7 (11%) 54 (89%)
  Chi-Squared χ2 = 3.4; p = 0.07
  BRCA1 mutated (n = 8) [Familial] 5 (62%) 3 (38%)
  Not BRCA1 mutated (n = 25) [Sporadic]b,c 2 (8%) 23 (92%)
  Chi-Squared χ2 = 7.8; p = 0.005
  BRCA1 Null/Weak (IHC < 10%) (n = 39) [Sporadic] 13 (33%) 26 (67%)
  BRCA1 positive (IHC ≥ 10%) (n = 236) [Sporadic]a 14 (6%) 222 (94%)
  Chi-Squared χ2 = 25.4; p = 5 x 10-7
PTEN   Negative (<1%) Positive (≥1%)
BRCA1 methylated (n = 18) [Sporadic] 7 (39%) 11 (61%)
Not BRCA1 methylated (n = 60) [Sporadic]b,c 12 (20%) 48 (80%)
Chi-Squared χ2 = 1.7; p = 0.18
BRCA1 mutated (n = 8) [Familial] 2 (25%) 6 (75%)
Not BRCA1 mutated (n = 26) [Sporadic]b,c 7 (27%) 19 (73%)
Chi-Squared χ2 = 0.1; p = 0.73
BRCA1 Null/Weak (IHC < 10%) (n = 40) [Sporadic] 17 (43%) 23 (57%)
BRCA1 positive (IHC ≥ 10%) (n = 237) [Sporadic]a 28 (12%) 209 (88%)
    Chi-Squared χ2 = 21.5; p = 3.6 x 10-6
aAll cases with available BRCA1 expression data, see also Figure 1B. bMatched against the corresponding BRCA1 affected group with respect to age- 
and year at diagnosis. cInformation not available for all 61 matched against BRCA1 methylation, or 27 matched against BRCA1 mutated tumors.644  Epigenetics  Volume 6 Issue 5www.landesbioscience.com Epigenetics  645
Figure 3. Ki-67 in triple-negative (TN) breast tumors. (A) The proportions of tumor cells undergoing proliferation, estimated by looking at Ki-67 on 
TMAs, were found to be significantly higher in TN tumors displaying loss of RB (TN/Claudin+/RB-) compared with the other two TN subroups (TN/
Claudin+/RB+ and TN/Claudin-Low). (B) The thresholds of optimal seperation for Ki-67 with respect to breast cancer-specific survival differ between 
luminal- and triple-negative subtypes. Here, Ki-67 does not identify prognostic subgroups within the HER2 subtype. (C) Kaplan-Meier plots, coupled 
with the log-rank test, demonstrating significantly more favorable disease outcome for patients with TN breast cancer displaying high levels of Ki-67 
positive tumor cells (left part). In contrast, highly proliferating tumors of the luminal phenotype are associated with significantly less favorable disease 
outcome (right part).
Figure 2 (See opposite page). Survival with respect to phenotype and RB/p16 dysfunction in TN breast cancers. (A) Breast cancer-specific survival 
with respect to phenotype without (left) and with (right) positivity for either EGFR or CK5/6 to define the basal-like phenotype. (B) The high/intense 
p16 expression pattern significantly associates with differential survival outcomes in TN breast cancer. (C) TN tumors lacking of Claudin-3 expression 
relate to reduced short-term survival. (D) Prognostic stratification of triple-negative breast cancer. Here, TN tumors lacking Claudin-3 are sub-cate-
gorized as TN/Claudin-, with the remainder of TN tumors subdivided based on the prescence/abscence of high p16 levels (IHC 3+), referred to as TN/
Claudin+/RB- (loss), or TN/Claudin+/RB+, respectively.646  Epigenetics  Volume 6 Issue 5
this context is that we observed low mortality rates associated 
with RB/p16 dysfunction in the TNBC subtype. These tumors 
display features indicative of DNA repair deficiency, includ-
ing CpG hypermethylation of the BRCA1 gene. Defects in 
DNA repair pathways confer enhanced sensitivity to specific 
DNA damaging agents depending on the pathways affected. 
In this relation, breast cancer patients with hormone-receptor 
negative disease are commonly offered drug combinations that 
may include either of the two DNA damaging agent’s cyclo-
phosphamide or mitoxantrone. The mode of action for cyclo-
phosphamide involves the formation of DNA adducts leading 
to crosslinks between and within DNA strands, and for mito-
xantrone in inhibiting the activity of topoisomerase leading to 
DNA double-strand breaks at replication forks during DNA 
synthesis. Under normal circumstances, these types of DNA 
damage are repaired by error-free homologous recombination, 
a process that requires functional BRCA1 gene products. The 
common use of these anti-cancer drugs in treatment of hor-
mone-receptor negative disease could explain the relation to 
favorable disease outcome for TNBCs with RB/p16 dysfunction 
as this phenotype is linked to BRCA1 defects. Interestingly and 
in support for this conclusion, platinum-based agents have been 
tested in patients with TNBC, and BRCA1 methylation was 
found to be predictive of response.40 It is noteworthy that the 
few claudin-low tumors identified here through IHC analysis of 
Claudin-3 (CLDN3) were related to poor disease outcome and 
showed low proliferative activity compared with the RB/p16 
dysfunctional type of TNBCs. In this relation, chemotherapy-
resistant tumors have been associated with features characteris-
tic of tumor initiating cells (TICs) which, in turn, are naturally 
enriched in the claudin-low subtype.6 The claudin-low pheno-
type has previously been associated with slower cell-cycling and 
poor prognosis.41 This low proliferation activity likely relates to 
their mammary stem cell characteristics. Lim et al. derived a 
differentiation model to show that BRCA1 mutated tumors are 
more similar to luminal progenitor cells rather than mammary 
stem cells.42 This seems consistent with the hypothesis of dif-
ferential TIC content in TNBCs, possibly explaining the dif-
ferences in proliferative activity and disease outcome observed 
here between the three subclasses TN/Claudin-, TN/Claudin+/
RB+ and TN/Claudin+/RBloss.
PARP inhibitors induce strong anti-tumor activity in patients 
with inherited BRCA1 or BRCA2 mutations.43 Given the high 
clinical benefit for mutation carriers, it is of considerable interest 
to determine whether subsets of sporadic breast cancer patients 
could also derive benefit from PARP inhibitors. Recently, the 
addition of PARP inhibitors to a combination of gemcitabine and 
carboplatin showed significant improvements in patients with 
metastatic TNBCs.44 The study of O’Shaughnessy et al. high-
light the importance of PARP inhibitors in treatment of TNBC 
patients, although reports on PARP inhibitors as single agent 
treatment in TNBC have not shown clinical benefits.2 Of poten-
tial importance in this respect is that PARP inhibitors can exert 
their anti-tumor effects in at least two independent ways; that is 
as single agents to induce synthetic lethality in tumors with HR 
defects (e.g., BRCA1 silencing) or by potentiating the effects of 
We demonstrate here, for the first time, a link between acquired 
CpG hypermethylation of the BRCA1 gene and RB/p16 dysfunc-
tion, and that these events are co-dependent in the development of 
TNBCs. Importantly, we show that the development of TNBCs 
in BRCA1 mutation carriers also depends on RB/p16 dysfunc-
tion. These results are consistent with our previous study, show-
ing two very different progression paths of TNBCs, of which one 
was highly associated with BRCA1 defects and extensive changes 
in DNA copy number indicative of genomic instability.18 Given 
these observations, we propose here that RB/p16 dysfunction in 
TNBCs reflects a biologically meaningful subtype of TNBCs, 
and that a key event in promoting the development of this phe-
notype is inactivation of the BRCA1 gene.
The functional importance of the relationship between 
BRCA1 defects and RB/p16 dysfunction could reflect the need 
to suppress the cellular response to DNA damage due to defec-
tive DNA repair following inactivation of the BRCA1 gene. It 
has been shown that acquired mutations in the TP53 (p53) gene 
is a characteristic feature of tumors derived from BRCA1 muta-
tion carriers.35 Our data, demonstrating a strong relationship 
between p53, p16 and pRb suggest cooperative effects for RB/
p16 dysfunction and mutations in the TP53 gene. Thus, both 
events could be required to fully suppress the DNA damage 
response in BRCA1 defective cells. Inactivation of the BRCA1 
gene leads to defective DNA repair of double-stranded breaks 
by error-free homologous recombination, leading to error-
prone non-homologous recombination (NHEJ).36 This leads 
to accelerated accumulation of genetic lesions, from which 
advantageous changes can arise and contribute to progression 
of the disease. It has been shown that tumors derived from 
BRCA1 mutation carriers acquire gross mutations in PTEN, 
involving genetic lesions consistent with inappropriate DNA 
repair.37 This is in line with results described here, showing loss 
of PTEN gene products in sporadic cases with acquired CpG 
island hypermethylation of the BRCA1 gene. However, only 
two of the BRCA1 mutated tumors were classified as PTEN 
null by IHC, although we note that in reviewing the arrays at 
least three additional cases were at borderline in this respect. 
The type of mutational mechanism affecting PTEN in BRCA1 
defective tumors could be at work in other genes as well, and it 
will therefore be of considerable interest to determine whether 
this will include the RB1 gene.
Treatment options for patients with triple-negative breast 
cancers (TNBCs) are limited as they are negative for the 
expression of estrogen-receptors (ER), progesterone-receptors 
(PR) and the human epidermal growth factor receptor type 
2 (HER2). Consequently, these patients are not responsive to 
tamoxifen for antagonizing the estrogen-receptor, or trasta-
zumab for inhibiting the activity of HER2. However, chemo-
therapy is very effective in hormone-receptor negative disease, 
including TNBC, whereas the same does not apply for patients 
with hormone-receptor positive disease i.e., the luminal sub-
type.38 It is important to note here that patients with TNBC 
are associated with poor prognosis, and this probably relates 
to the highly aggressive behavior seen following progression 
of TNBCs to metastatic disease.39 Of considerable interest in www.landesbioscience.com Epigenetics  647
representative region enriched for tumor cells from archived for-
malin fixed and paraffin-embedded (FFPE) tumor tissue as pre-
viously described in reference 18. TMAs representing three core 
samples from each case were studied using immunohistochemis-
try (IHC) for expression analysis of subtype-specific biomarkers, 
that is ER, PR, HER2, Ki-67, CK5/6 and EGFR, along with 
Claudin-3, coupled with additional selection of eight basal-linked 
markers based on published literature, i.e., BRCA1, p53 (TP53), 
PTEN, p16 (CDKN2A), pRb (RB1), MUC1, CK8 (KRT8), 
CK18 (KRT18). IHC expression analysis was performed as pre-
viously described in reference 18.
Breast cancer subtypes were assigned to using the five bio-
marker scheme based on estrogen receptor (ER), progester-
one receptor (PR), human epidermal growth factor receptor 2 
(HER-2), epidermal growth factor receptor (EGFR) and cyto-
keratin 5/6 (CK5/6).27 Expression of ER and PR were scored 
positive (IHC score ≥1+) when IHC staining was observed in 
more than 1% of tumor cell nuclei. HER-2 positivity was scored 
for strong membranous staining (IHC score 3+) whereas EGFR 
was scored positive for any, weak or strong, membranous stain-
ing (IHC score ≥1+). Expression of CK5/6 was defined positive 
when cytoplasmic and/or membranous staining was observed 
and otherwise considered negative. Hormone-receptor positive 
tumors, those positive for either ER or PR, were assigned to 
the luminal subtype. Tumors negative for ER, PR and HER-2 
were categorized as triple-negative (TN). Complete absence of 
Claudin-3 gene products in TN tumors were classified as TN/
Claudin-Low, with the basal-like phenotype assigned to the 
remaining tumors (TN) where either EGFR or CK5/6 were 
expressed. Tumors negative for ER and PR negative tumors, 
but displaying HER-2 positivity (IHC 3+) were assigned to the 
HER2 subtype. Here, overexpression of HER2 (IHC 3+) was 
identified in 33 of 284 informative cases (33 of 284; 11.6%) of 
which 19 were hormone-receptor negative, thereby classified as 
HER2 subtype. Estimates for the expression of MKI67 (Ki-67) 
gene products represent counts for the proportion of positive 
tumor cells, based on nuclear expression, reported on a scale 
from 0.0–1.0 within intervals of 0.05. Luminal tumors showing 
Ki-67 expression ≥0.15 were assigned to the luminal B subtype 
whereas the remaining part was considered luminal A.28
The expression of BRCA1 was estimated on a discontinuous 
scale, based on counts for the proportion of tumor cells showing 
nuclear expression, Null/Weak (0; <10%), Intermediate (1+/2+; 
10%–50%) and Strong (3+; >50%). Similarly, expression of p16 
(CDKN2A), pRb (RB1) and p53 were scored by counting posi-
tively staining nuclei, i.e., Null/Weak 0 (<10%), Intermediate 1+ 
(10–25%), 2+ (25–50%) and Strong 3+ (>50%). In estimating 
p16, the highest score of 3+ almost invariably involved intense 
and diffuse cytoplasmic and nuclear staining, and therefore 
referred to as high/intense p16 (IHC Score 3+). Expression of 
PTEN was determined negative or positive based on the absence 
or presence of cytoplasmic IHC staining, respectively. MUC1, 
CK8 and CK18 were estimated by looking at cytoplasmic 
and/or membranous staining on the scale of Low (0; <10%), 
Intermediate (1+/2+; 10%–80%) and High (3+; >80%). The 
DNA damaging agents.45 More comprehensive understanding of 
TNBCs is therefore essential to effectively guide the use of PARP 
inhibitors in clinical management of these patients. The potential 
importance of epigenetic inactivation of the BRCA1 gene in this 
relation has been demonstrated in a pre-clinical study.46 Thus, 
CpG island hypermethylation of the BRCA1 gene could be an 
important marker in TNBCs for predicting response to PARP 
inhibitors, platinum-based drugs, or other agents leading to dou-
ble-strand breaks.
In conclusion, our findings are consistent with a causative link 
between defects in the BRCA1 gene by CpG island hypermethyl-
ation and the development of TNBCs characterized by RB/p16 
dysfunction in sporadic cases of the disease.
Materials and Methods
Study group. The study group of 303 patients was derived from 
a well defined sample collection previously screened for the local 
5193G→A BRCA1 and 999del5 BRCA2 germline founder muta-
tions.23,24 Extensive population and family studies have indicated 
that these two mutations account for all BRCA mutation related 
breast cancer risk in the population.25,26 This is also supported by 
findings of the Cancer Genetic Counseling Clinic of the National 
University Hospital in Iceland. The patients were all diagnosed 
and treated at the same institution, the National University 
Hospital. Of the 303 cases, a total of 292 were derived from 
sporadic cases, of which 111 had previously been studied with 
respect to CpG island hypermethylation of the BRCA1 gene.17,18 
Additionally, we included a selected set of breast tumors derived 
from 8 individuals carrying the same 5193G→A BRCA1 germ-
line mutation, as well as three from carriers of a polymorphism in 
the BRCA1 gene were included in the study group. The BRCA1 
polymorphism is a base change from A to T affecting codon 1675 
predicted to result in a single amino-acid change from Thr to Ser, 
and is currently of unknown clinical significance with respect to 
breast cancer risk. Sporadic cases were defined as those arising in 
non-BRCA carriers, i.e., individuals negative for the 5193G→A 
BRCA1 and 999del5 BRCA2 mutations and having negative fam-
ily history for breast cancer.
Information on patient age and date of diagnosis were obtained 
from the Icelandic Cancer Registry. Matching for age- and year 
at diagnosis was carried out to compare BRCA1 affected and 
non-affected tumors with respect to phenotype and breast cancer-
specific survival. Age- and year at diagnosis within a range of ±3 
years was achieved in all but two of non-BRCA1 affected tumors 
matched for each of BRCA1 methylated- and BRCA1 mutated 
tumors (Sup. Fig. 1A). The number of selected tumors was targeted 
at four non-BRCA1 affected cases for each one of BRCA1 affected 
cases. This was achieved in 14 of 26 BRCA1 affected tumors, with 
all but three of the remaining 12 BRCA1 affected tumors having 
at least three matched non-BRCA1 affected tumors. This yielded 
highly similar distribution of age- and year at diagnosis between 
BRCA1 affected, and non-BRCA1 affected cases (Sup. Fig. 1B).
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microarrays (TMA) were constructed by selecting viable and 648  Epigenetics  Volume 6 Issue 5
28.  Cheang MC, Chia SK, Voduc D, Gao D, Leung S, 
Snider J, et al. Ki67 index, HER2 status and prognosis 
of patients with luminal B breast cancer. J Natl Cancer 
Inst 2009; 101:736-50.
29.  Chenevix-Trench G, Healey S, Lakhani S, Waring P, 
Cummings M, Brinkworth R, et al. Genetic and his-
topathologic evaluation of BRCA1 and BRCA2 DNA 
sequence variants of unknown clinical significance. 
Cancer Res 2006; 66:2019-27.
30.  Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative 
breast cancer. N Engl J Med 363:1938-48.
31. Catteau A, Harris WH, Xu CF, Solomon E. 
Methylation of the BRCA1 promoter region in spo-
radic breast and ovarian cancer: correlation with disease 
characteristics. Oncogene 1999; 18:1957-65.
32.  Gauthier ML, Berman HK, Miller C, Kozakeiwicz K, 
Chew K, Moore D, et al. Abrogated response to cel-
lular stress identifies DCIS associated with subsequent 
tumor events and defines basal-like breast tumors. 
Cancer Cell 2007; 12:479-91.
33.  Liao CC, Tsai CY, Chang WC, Lee WH, Wang JM. 
RB.E2F1 complex mediates DNA damage responses 
through transcriptional regulation of ZBRK1. J Biol 
Chem 285:33134-43.
34.  Herschkowitz JI, He X, Fan C, Perou CM. The func-
tional loss of the retinoblastoma tumour suppressor 
is a common event in basal-like and luminal B breast 
carcinomas. Breast Cancer Res 2008; 10:75.
35.  Holstege H, Joosse SA, van Oostrom CT, Nederlof 
PM, de Vries A, Jonkers J. High incidence of protein-
truncating Tp53 mutations in BRCA1-related breast 
cancer. Cancer Res 2009; 69:3625-33.
36.  Gudmundsdottir K, Ashworth A. The roles of BRCA1 
and BRCA2 and associated proteins in the main-
tenance of genomic stability. Oncogene 2006; 25: 
5864-74.
37.  Saal LH, Gruvberger-Saal SK, Persson C, Lovgren K, 
Jumppanen M, Staaf J, et al. Recurrent gross mutations 
of the PTEN tumor suppressor gene in breast cancers 
with deficient DSB repair. Nat Genet 2008; 40:102-7.
38.  Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini 
O, Veronesi P, et al. Chemotherapy is more effective 
in patients with breast cancer not expressing steroid 
hormone receptors: a study of preoperative treatment. 
Clin Cancer Res 2004; 10:6622-8.
39.  Kassam F, Enright K, Dent R, Dranitsaris G, Myers 
J, Flynn C, et al. Survival outcomes for patients with 
metastatic triple-negative breast cancer: implications 
for clinical practice and trial design. Clin Breast Cancer 
2009; 9:29-33.
40.  Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi 
Z, Li Q, et al. Efficacy of neoadjuvant Cisplatin in triple-
negative breast cancer. J Clin Oncol 28:1145-53.
41.  Prat A, Perou CM. Deconstructing the molecular por-
traits of breast cancer. Mol Oncol 5:5-23.
42.  Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, 
et al. Aberrant luminal progenitors as the candidate tar-
get population for basal tumor development in BRCA1 
mutation carriers. Nat Med 2009; 15:907-13.
15.  Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-
Guiu X, Lerma E, et al. Promoter hypermethylation 
and BRCA1 inactivation in sporadic breast and ovarian 
tumors. J Natl Cancer Inst 2000; 92:564-9.
16.  Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, 
Sveen L, et al. BRCA1 promoter methylation in spo-
radic breast cancer is associated with reduced BRCA1 
copy number and chromosome 17 aneusomy. Cancer 
Res 2005; 65:10692-9.
17.  Birgisdottir V, Stefansson OA, Bodvarsdottir SK, 
Hilmarsdottir H, Jonasson JG, Eyfjord JE. Epigenetic 
silencing and deletion of the BRCA1 gene in sporadic 
breast cancer. Breast Cancer Res 2006; 8:38.
18. Stefansson OA, Jonasson JG, Johannsson OT, 
Olafsdottir K, Steinarsdottir M, Valgeirsdottir S, et 
al. Genomic profiling of breast tumours in relation to 
BRCA abnormalities and phenotypes. Breast Cancer 
Res 2009; 11:47.
19.  Turner NC, Reis-Filho JS, Russell AM, Springall 
RJ, Ryder K, Steele D, et al. BRCA1 dysfunction in 
sporadic basal-like breast cancer. Oncogene 2007; 
26:2126-32.
20.  Rakha EA, El-Sheikh SE, Kandil MA, El-Sayed ME, 
Green AR, Ellis IO. Expression of BRCA1 protein 
in breast cancer and its prognostic significance. Hum 
Pathol 2008; 39:857-65.
21.  Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown 
M, Miron A, et al. Ganesan S: X chromosomal abnor-
malities in basal-like human breast cancer. Cancer Cell 
2006; 9:121-32.
22.  Matros E, Wang ZC, Lodeiro G, Miron A, Iglehart 
JD, Richardson AL. BRCA1 promoter methylation in 
sporadic breast tumors: relationship to gene expression 
profiles. Breast Cancer Res Treat 2005; 91:179-86.
23.  Bergthorsson JT, Jonasdottir A, Johannesdottir G, 
Arason A, Egilsson V, Gayther S, et al. Identification of 
a novel splice-site mutation of the BRCA1 gene in two 
breast cancer families: screening reveals low frequency 
in Icelandic breast cancer patients. Hum Mutat 1998; 
1:195-7.
24. Thorlacius S, Olafsdottir G, Tryggvadottir L, 
Neuhausen S, Jonasson JG, Tavtigian SV, et al. A single 
BRCA2 mutation in male and female breast cancer 
families from Iceland with varied cancer phenotypes. 
Nat Genet 1996; 13:117-9.
25.  Thorlacius S, Sigurdsson S, Bjarnadottir H, Olafsdottir 
G, Jonasson JG, Tryggvadottir L, et al. Study of a single 
BRCA2 mutation with high carrier frequency in a small 
population. Am J Hum Genet 1997; 60:1079-84.
26.  Tryggvadottir L, Sigvaldason H, Olafsdottir GH, 
Jonasson JG, Jonsson T, Tulinius H, et al. Population-
based study of changing breast cancer risk in Icelandic 
BRCA2 mutation carriers 1920–2000. J Natl Cancer 
Inst 2006; 98:116-22.
27.  Cheang MC, Voduc D, Bajdik C, Leung S, McKinney 
S, Chia SKP, et al. Basal-like breast cancer defined by 
five biomarkers has superior prognostic value than 
triple-negative phenotype. Clin Cancer Res 2008; 
14:1368-76.
References
1.  Schneider BP, Winer EP, Foulkes WD, Garber J, Perou 
CM, Richardson A, et al. Triple-negative breast cancer: 
risk factors to potential targets. Clin Cancer Res 2008; 
14:8010-8.
2.  Anders CK, Winer EP, Ford JM, Dent R, Silver DP, 
Sledge GW, et al. Poly(ADP-Ribose) polymerase inhi-
bition: “Targeted” therapy for triple-negative breast 
cancer. Clin Cancer Res 16:4702-10.
3.  Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, 
Nobel A, et al. Repeated observation of breast tumor 
subtypes in independent gene expression data sets. Proc 
Natl Acad Sci USA 2003; 100:8418-23.
4.  Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, 
Hu Z, et al. Immunohistochemical and clinical char-
acterization of the basal-like subtype of invasive breast 
carcinoma. Clin Cancer Res 2004; 10:5367-74.
5.  Prat A, Parker JS, Karginova O, Fan C, Livasy C, 
Herschkowitz JI, et al. Phenotypic and molecular 
characterization of the claudin-low intrinsic subtype of 
breast cancer. Breast Cancer Res 2010; 12:68.
6.  Creighton CJ, Li X, Landis M, Dixon JM, Neumeister 
VM, Sjolund A, et al. Residual breast cancers after 
conventional therapy display mesenchymal as well as 
tumor-initiating features. Proc Natl Acad Sci USA 
2009; 106:13820-5.
7.  Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, 
Harshman K, Tavtigian S, et al. A strong candidate 
for the breast and ovarian cancer susceptibility gene 
BRCA1. Science 1994; 266:66-71.
8.  Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, 
van der Vijver M, Parry S, et al. Prediction of BRCA1 
status in patients with breast cancer using estrogen 
receptor and basal phenotype. Clin Cancer Res 2005; 
11:5175-80.
9.  Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, 
Goffin JR, Wong N, et al. Germline BRCA1 mutations 
and a basal epithelial phenotype in breast cancer. J Natl 
Cancer Inst 2003; 95:1482-5.
10.  Melchor L, Honrado E, Garcia MJ, Alvarez S, Palacios 
J, Osorio A, et al. Distinct genomic aberration patterns 
are found in familial breast cancer associated with 
different immunohistochemical subtypes. Oncogene 
2008; 27:3165-75.
11.  van Beers EH, van Welsem T, Wessels LF, Li Y, 
Oldenburg RA, Devilee P, et al. Comparative genomic 
hybridization profiles in human BRCA1 and BRCA2 
breast tumors highlight differential sets of genomic 
aberrations. Cancer Res 2005; 65:822-7.
12. Turner N, Tutt A, Ashworth A. Hallmarks of 
‘BRCAness’ in sporadic cancers. Nat Rev Cancer 2004; 
4:814-9.
13.  Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, 
Harshman K, Tavtigian S, et al. BRCA1 mutations in 
primary breast and ovarian carcinomas. Science 1994; 
266:120-2.
14.  Esteller M. Epigenetics in cancer. N Engl J Med 2008; 
358:1148-59.
Acknowledgments
The authors would like to thank The Icelandic Cancer Registry 
for their support in providing data on clinical parameters 
and patient survival. This work was funded by Eimskipafelag 
University Fund (O.A.S.), Minningarsjodur Bergthoru 
Magnusdottur & Jakobs J Bjarnasonar (O.A.S.), Gongum 
Saman (O.A.S.), Icelandic Centre for Research RANNIS 
(O.A.S., J.G.J., O.T.J., J.E.E.), The University of Iceland 
Research Fund (O.A.S., J.E.E.).
Note
Supplemental materials can be found at:
www.landesbioscience.com/journals/epigenetics/article/15667
antibodies and dilutions used in IHC expression analysis are 
listed in Supplemental Table 1.
Data analysis. Tabular data were analyzed by the chi-squared 
hypothesis test, using the chisq.test function in R 2.12.0. 
Hierarchical cluster analysis was performed using the heatmap 
function in R, with Euclidean distance as a measure of similarity 
and average linkage (cluster package in R 2.12.0). Differences in 
survival outcomes were compared by the log-rank statistic, and 
Cox proportional hazards model using R 2.12.0 (survival pack-
age). In all cases, the end-point was defined as breast cancer-spe-
cific survival from the time (days) of diagnosis. The underlying 
assumptions of proportionality for Cox hazards regression were 
assessed using the cox.zph function (R 2.12.0; survival package).www.landesbioscience.com Epigenetics  649
45.  Annunziata CM, O’Shaughnessy J. Poly (ADP-ribose) 
polymerase as a novel therapeutic target in cancer. Clin 
Cancer Res. 2010; 16:4517-26.
46.  Veeck J, Ropero S, Setien F, Gonzalez-Suarez E, Osorio 
A, Benitez J, et al. BRCA1 CpG island hypermethylation 
predicts sensitivity to poly(adenosine diphosphate)-
ribose polymerase inhibitors. J Clin Oncol 28:563-64.
43.  Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-
Roelvink M, et al. Inhibition of poly(ADP-ribose) 
polymerase in tumors from BRCA mutation carriers. 
N Engl J Med 2009; 361:123-34.
44.  O’Shaughnessy J, Osborne C, Pippen JE, Yoffe M, 
Patt D, Rocha C, et al. Iniparib plus chemotherapy in 
metastatic triple-negative breast cancer. N Engl J Med 
364:205-14.